Provided by Tiger Fintech (Singapore) Pte. Ltd.

Prelude Therapeutics Inc

0.6750
-0.0331-4.67%
Post-market: 0.70000.0250+3.70%18:57 EDT
Volume:195.73K
Turnover:131.83K
Market Cap:37.23M
PE:-0.40
High:0.7050
Open:0.7001
Low:0.6561
Close:0.7081
Loading ...

3 Promising Penny Stocks With Market Caps Up To $300M

Simply Wall St.
·
01 Apr

Prelude Therapeutics Founder Acquires 28% More Stock

Simply Wall St.
·
29 Mar

Prelude Therapeutics CEO Makes Bold Stock Purchase!

TIPRANKS
·
19 Mar

Prelude Therapeutics Reports 2024 Financial Results

TIPRANKS
·
11 Mar

Prelude Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
11 Mar

Prelude Therapeutics FY Sales $7.000M Beat $2.000M Estimate

Benzinga
·
10 Mar

Prelude Therapeutics reports FY24 EPS ($1.68), consensus ($1.77)

TIPRANKS
·
10 Mar

Prelude Therapeutics sees cash runway into 2Q26

TIPRANKS
·
10 Mar

BRIEF-Prelude Therapeutics FY Operating Expenses USD 146.714 Million

Reuters
·
10 Mar

Prelude Therapeutics FY Operating Expenses USD 146.714 Million

THOMSON REUTERS
·
10 Mar

Press Release: Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025

Dow Jones
·
10 Mar

Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference

GlobeNewswire
·
05 Mar

Prelude Therapeutics Inc expected to post a loss of 47 cents a share - Earnings Preview

Reuters
·
11 Feb

BRIEF-Prelude Therapeutics Names Bryant Lim As Permanent CFO

Reuters
·
06 Feb

Prelude Therapeutics Appoints Bryant D. Lim as CFO

TIPRANKS
·
06 Feb

Prelude Therapeutics Inc - Appoints Bryant D. Lim as Permanent CFO

THOMSON REUTERS
·
06 Feb

Krishna Vaddi Bought 4.9% More Shares In Prelude Therapeutics

Simply Wall St.
·
22 Dec 2024

Prelude Therapeutics (PRLD) Gets a Sell from Morgan Stanley

TIPRANKS
·
12 Dec 2024

BRIEF-Prelude Therapeutics Presents Preliminary Results Of Phase 1 Dose-Escalation Study Of PRT2527 As Monotherapy And In Combination With Zanubrutinib

Reuters
·
11 Dec 2024

Prelude Therapeutics presents first interim data from trial of PRT2527

TIPRANKS
·
11 Dec 2024